

Quote by Nilaya Varma, Group CEO & Co-Founder, Primus Partners

Published in Business Standard

September 17, 2025

**Novartis Vymada patent revoked, generics set to slash prices by 70%**

# Novartis' Vymada patent revoked, generics set to slash prices by 70%

The Indian Patent Office's decision to revoke Novartis' patent on its blockbuster cardiac drug, Vymada, is set to reshape the country's ₹550 crore market for the therapy.

The move opens the floodgates for generic competition, likely slashing prices by over 70 per cent and significantly improving access for India's vast cardiovascular patient base.

Vymada, considered among the most important cardiology drugs globally, commands 2.4 per cent of India's ₹23,000 crore cardiac drug segment.

"Vymada holds a significant presence in India, with sales of around ₹550 crore," said Group CEO and cofounder, Primus Partners, Nilaya Varma.

The Patent Office, in its ruling, said Novartis' patent lacked novelty and technical advancement, noting that the company had failed to show enhanced therapeutic efficacy or comparative benefits of its supra-molecular complex over prior disclosures.

BS REPORTER

More on [business-standard.com](https://business-standard.com)